Home›Stocks›CRSP

CRSP — structural market context

CRISPR Therapeutics AG

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 16. Each line shows the earlier value, the later value and their dates.

Price

Close $49.25 (Oct 16) vs $51.52 (Oct 15): −4.41%.

Volume

0.89× its 20-session average (1.7M) on Oct 16.

Includes pre- and post-market trading.

Short interest

Short interest 18.7M shares (settlement Sep 30) vs 19.1M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 6 days with fails, largest 7K shares on Sep 15.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 5 days with fails, largest 14K shares on Sep 11.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

1 Form 4 filing recorded, with 3 transactions: 0 purchase transactions (code P, $0), 1 sale transaction (code S, $720K).

Filed Oct 16. Form 4 data arrives about a day after filing.

1 filing not counted: the filed price could not be checked against the U.S. listing.

CRSP short interest & days to cover

SHARES SHORT
18.7M
% OF FLOAT
—
DAYS TO COVER
9.6
CHANGE VS PRIOR
-2.0%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (16d ago)

CRSP fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-30 · 16d102$56
2026-09-29 · 17d834$54.09
2026-09-22 · 24d6K$58.33

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

CRSP insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 5 sales

InsiderTypeSharesValueFiled
KASINGER JAMES R. · officer: General Counsel and SecretarySell (S)1K$51K2026-10-15
Kulkarni Samarth · director, officer: Chief Executive OfficerSell (S)4K$202K2026-10-15
KASINGER JAMES R. · officer: General Counsel and SecretarySell (S)2K$119K2026-10-08
KASINGER JAMES R. · officer: General Counsel and SecretarySell (S)10K$626K2026-09-24
Behbahani Ali · directorSell (S)14K$781K2026-09-21

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

CRSP analyst ratings

FirmActionRatingPublished
UBSinitialiseNeutral (from Buy)2026-10-15
UBSprice_target—2026-10-15
H.C. WainwrightholdBuy2026-10-09
UBSholdBuy2026-10-09
CitigroupholdMarket Outperform2026-09-28

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying CRSP?
In the last 12 months of SEC Form 4 filings, CRSP recorded 0 insider purchases and 5 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about CRSP?
The most recent action: UBS initialise to Neutral on 2026-10-15. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell CRSP?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with C

CLF · Cleveland-Cliffs Inc.CAI · Caris Life Sciences, Inc. CommCASY · Casey's General Stores, Inc. CCATX · Perspective Therapeutics, Inc.CBLL · CeriBell, Inc.CHPT · ChargePoint Holdings, Inc.All C →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.